All In Biotech

Drug Trial Radar · NCT05785390

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase IIa/IIb Study to Evaluate the Safety, Tolerability, and Efficacy of NP-101 in Treating High-Risk Participants Who Have Tested Positive for Novel Coronavirus 2019.

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

170

Actual

Start

Feb 22, 2023

Primary completion

May 9, 2025

Study completion May 9, 2025

Sponsor

Lead sponsor
Novatek PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19. The main question\[s\] it aims to answer are: * To evaluate the safety of NP-101, as well as establish the maximum tolerated dose in high risk Covid-19 positive patients. Participants will \[describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items\]. If there is a comparison group: Researchers will compare \[insert groups\] to see if \[insert effects\].

Conditions

  • COVID-19

Interventions

  • NP-101Drug

    NP-101 is an organically derived, GMP manufactured product covered under IND #152687.

  • PlaceboOther

    Identical placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Establishment of MTDDTime frame: Fourteen days per dose (Phase IIA Only)
  2. Safety and Tolerability of NP-101 vs Placebo (Phase IIa and IIb)Time frame: Through Day 45
  3. Time to Sustained Clinical RecoveryTime frame: Through Day 5

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • L&A Morales Healthcare/ Enrique Villa, MD Principal Investigator

    Miami, Florida

  • Research Network America

    Berwyn, Illinois

  • Clinical Trial Network

    Houston, Texas

  • Pearland Family Wellness Clinic

    Pearland, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.